RecruitingPhase 2NCT05607108

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

13 participants

Start Date

Nov 1, 2022

Study Type

INTERVENTIONAL

Conditions

Squamous Cell Lung Cancer

Summary

The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a drug called ZEN003694 for people with squamous cell lung cancer (a type of lung cancer) whose tumors have a specific genetic change called NSD3 gain or amplification, which is detected through genetic testing. **You may be eligible if...** - You have confirmed squamous cell lung cancer that has returned or spread - Your tumor has an NSD3 gene gain or amplification confirmed by genetic (NGS) testing - You have already received platinum-based chemotherapy plus immunotherapy as first-line treatment - Your performance status is ECOG 0–2 (able to carry out daily activities with minimal limitations) - You have brain metastases that are small and not causing symptoms (under certain conditions) **You may NOT be eligible if...** - Your tumor does not have NSD3 amplification/gain - You have not yet received first-line treatment - Your overall health is too poor to tolerate the study treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.